KRAS and non-small cell lung carcinoma: Comparing these results with studies such as National Cancer Institute of Canada Clinical Trials group Study BR.21,17 which reported successful KRAS mutation analysis in 206/230 (89.6%) of NSCLC samples, we are clearly demonstrating a successful optimisation and validation strategy.